REMICADE (infliximab) is no longer covered on the Reformulary. There are several infliximab biosimilars, including INFLECTRA, RENFLEXIS, AVSOLA covered on the Reformulary. All infliximab biosimilars require Special Authorization.
Biosimilars are safe and clinically similar to the originator biologic, and have the potential to provide significant savings to you and your plan – this is essential to drug plan sustainability.
REMICADE is used to treat
Inflammatory Bowel Disease (IBD)